Patent Assignment
Reel/Frame 019783/0625
Change of Name
Recorded: 2007-09-04
Pages: 8
Assignor
ALTANA PHARMA AG
Executed: 2007-06-14
Assignee
NYCOMED GMBH
BKY-GULDEN-STR. 2, 78467 KONSTANZ, GERMANY
Covered Properties
(84)
Process for the rehydration of magaldrate powder
Application:
10/399,713 →
Publication:
US US20040018249A1
Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Application:
11/501,836 →
Publication:
US US20060269600A1
Freeze-Dried Pantoprazole Preparation and Pantoprazole Injection
Pharmaceutical Preparation in the Form of a Supension Comprising an Acid-Labile Active Ingredient
Process for Preparing Optically Pure Active Compounds
Combination of Roflumilast with Methotrexate
Application:
10/184,068 →
Publication:
US US20030092706A1
Process for the Production of 16,17-[{Cyclohexylmethylen)Bis(Oxy)]-11,21-Dihydroxy-Pregna-1,4-Dien-3,20-Dion or Its 21-Isobutyrat by Transketalisation
Oral Dosage Form Containing a Pde 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient
Pharmaceutical Preparation in the Form of a Paste Comprising an Acid-Labile Active Ingredient
Pharmaceutical Preparation Comprising an Active Dispersed on a Matrix
Ciclesonide Containing Aqueous Pharmaceutical Composition
Patent:
8,383,611 →
Application:
10/110,632 →
Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
Application:
10/506,875 →
Publication:
US US20050112069A1
Combination
Application:
10/489,903 →
Publication:
US US20050014762A1
Pantoprazole cyclodextrin inclusion complexes
Application:
10/501,295 →
Publication:
US US20050171057A1
Topically applicable pharmaceutical preparation
Application:
10/515,698 →
Publication:
US US20060084684A1
Process for preparing crystalline ciclesonide with defined particle size
Novel Process for the Preparation of Roflumilast
Use of PDE4 Inhibitors for the Treatment of Diabetes Mellitus
2-Hydroxy-6-Phenylphenanthridines as Pde-4 Inhibitors
3-Hydroxy-6-Phenylphenanthridines as Pde-4 Inhibitors
Use of the Combination of Ciclesonide and Antihistamines for the Treatment of Allergic Rhinitis
Salt of (S)-Pantoprazole and Its Hydrates
Synergistic combination comprising roflumilast and (r,r) - formoterol
Application:
10/535,817 →
Publication:
US US20060199865A1
Synergistic combination comprising roflumilast and formoterol
Application:
10/535,816 →
Publication:
US US20060142308A1
Novel Preparation and Administration Form Comprising an Acid-Labile Active Compound
Patent:
7,794,752 →
Application:
09/980,492 →
Process for Preparing (S)-Pantoprazole
Combination of a Nsaid and a Pde-4 Inhibitor
Application:
10/489,920 →
Publication:
US US20040242597A1
Ophthalmological use of roflumilast for the treatment of diseases of the eye
Application:
10/515,896 →
Publication:
US US20060084685A1
Ciclesonide-Containing Sterile Aqueous Suspension
Combination Medicament
Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
Application:
10/542,088 →
Publication:
US US20060148804A1
Dosage form containing pantoprazole as active ingredient
Application:
10/555,238 →
Publication:
US US20060240100A1
Evaporator refrigeration system vehicle equipped with said system and method of evaporating refrigerant
Application:
10/555,311 →
Publication:
US US20060288733A1
Salmeterol and ciclesonide combination
Application:
10/556,863 →
Publication:
US US20060293293A1
Composition comprising a pde4 inhibitor and a pde5 inhibitor
Application:
10/556,888 →
Publication:
US US20060094723A1
Formoterol and Ciclesonide Combination
Alkaline salts of proton pump inhibitors
Application:
10/564,768 →
Publication:
US US20060189590A1
Pharmaceutical Product For Injection
Application:
10/568,417 →
Publication:
US US20080167349A1
Use of Surfactant Preparations for the Treatment of Surgical Adhesions
Application:
10/568,816 →
Publication:
US US20090011978A1
Composition comprising a pulmonary surfactant and a pde2 inhibitor
Application:
10/568,817 →
Publication:
US US20060229242A1
Use of ciclesonide for the treatment of inflammatory bowel diseases
Application:
10/570,986 →
Publication:
US US20060211668A1
Use of Ciclesonide for the Treatment of Respiratory Diseases
Compliance monitor and method
Novel Medicine Pack
Novel Salts of Pantoprazole and (S) - Pantoprazole
Application:
10/586,753 →
Publication:
US US20080234326A1
Pyridazinone Derivatives and their Use as Pde4 Inhibitors
Application:
10/587,830 →
Publication:
US US20080227790A1
2-(Piperidin-4-Yl)-4,5-Dihydro-2H-Pyridazin-3-One Derivatives as PDE4 Inhibitors
Phthalazinone derivatives as pde4 inhibitors
Application:
10/587,840 →
Novel Guanidinyl-Substituted Hydroxy-6-Phenylphenanthridines as Effective Phosphodiesterase (Pde) 4 Inhibitors
Roflumilast and glycopyrronium combination
Application:
10/589,865 →
Publication:
US US20070167496A1
Ciclesonide and glycopyrronium combination
Application:
10/589,871 →
Publication:
US US20070185067A1
Novel Hydroxy-6-Heteroarylphenanthridines and Their Use as PDE4 Inhibitors
Novel heterocycle-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
Application:
10/590,805 →
Publication:
US US20070191413A1
Novel Use for PDE5 Inhibitors
Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors
Application:
10/591,472 →
Publication:
US US20070259909A1
Novel Sulfonylpyrroles
Novel isoamido-substituted hydroxy-6-phenylphenanthridines
Application:
10/591,478 →
Publication:
US US20070191414A1
Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
Application:
10/591,480 →
Publication:
US US20070185149A1
Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors
Application:
10/591,768 →
Publication:
US US20080161339A1
Novel Preparation and Administration Form Comprising an Acid-Labile Active Compound
Oral Administration Form for Pyridin-2-Ylmethylsulfinyl-1H-Benzimidazoles
Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation
Application:
11/413,197 →
Publication:
US US20060194732A1
Synergistic combination
Application:
11/433,419 →
Publication:
US US20060205806A1
Use of Ciclesonide for the Treatment of Respiratory Diseases in a Smoking Patient
Application:
11/578,294 →
Publication:
US US20070134165A1
Dialkoxy-Imidazopyridines Derivatives
Application:
11/578,844 →
Publication:
US US20070219236A1
Novel Pharmaceutical Dosage Form and Manufacturing Process
Application:
11/579,134 →
Publication:
US US20070231388A1
Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
Application:
11/579,375 →
Publication:
US US20070254928A1
Method of classifying gerd
Application:
11/587,274 →
Publication:
US US20070179364A1
Blinding Device
Application:
11/587,945 →
Publication:
US US20070272236A1
Device and Method for Monitoring the Functioning of the Lower Esophageal Sphincter
Application:
11/596,805 →
Publication:
US US20080033274A1
Method for Identifying PDE5-Modulators
Application:
11/596,990 →
Publication:
US US20090087871A1
Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds
Application:
11/597,373 →
Publication:
US US20070225500A1
Amino-Halogen-Imidazopyridines as Proton Pump Inhibitors
Application:
11/628,649 →
Publication:
US US20070244115A1
4,6-Disubstituted Pyrimidines and Their Use as Protein Kinase Inhibitors
Composition Comprising a Pulmonary Surfactant and a Tnf-Derived Peptide
Benzothienopyridines for Use as Inhibitors of EG5 Kinesin
Triazolophthalazines
Pyrazolo[1,5-C]Pyrimidines
Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
Application:
11/661,150 →
Publication:
US US20080027034A1
Novel 3-Oxa-10-Aza-Phenanthrenes
Novel 3-Thia-10-Aza-Phenanthrene Derivatives
Aqueous Pharmaceutical Preparation Comprising Roflumilast
Pharmaceutical Composition Comprising Roflumilast or the N-Oxide of Roflumilast
Application:
11/662,888 →
Publication:
US US20080045572A1
Aqueous suspensions of ciclesonide for nebulisation
Application:
10/582,499 →
Publication:
US US20070117783A1
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 15, 2010
From: NYCOMED GMBH
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023934/0703 →
Change of Name
Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
Change of Name
Jan 30, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 034862/0060 →
Merger
Jan 30, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 034869/0899 →
Merger
Jan 30, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 034869/0936 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0224 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0478 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0179 →
Assignment of Assignor's Interest
Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
Assignment of Assignor's Interest
Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
Security Interest
Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
Security Interest
Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
Release of Security Interest
Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
Business Transfer and Contribution Agreement
Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
Security Interest
Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
Notice of Grant of Security Interest in Intellectual Property (First Lien)
Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
Notice of Grant of Security Interest in Intellectual Property (Second Lien)
Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →
Release of Security Interest
Jun 2, 2023
From: BARCLAYS BANK PLC
To: COVIS PHARMA GMBH
Reel/Frame 063841/0208 →
Release of Security Interest in Patents
Mar 17, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA GMBH
Reel/Frame 070537/0122 →
Confirmatory Grant of Security Interest in United States Patents
May 27, 2025
From: COVIS PHARMA GBMH
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 071409/0368 →